Roth MKM Downgrades Rain Oncology to Neutral, Announces $1.2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Raja Kumaraguru downgraded Rain Oncology (NASDAQ:RAIN) from Buy to Neutral and announced a $1.2 price target.
May 30, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Rain Oncology downgraded from Buy to Neutral by Roth MKM analyst Raja Kumaraguru, with a new price target of $1.2.
The downgrade from Buy to Neutral by Roth MKM analyst Raja Kumaraguru indicates a less optimistic outlook on Rain Oncology's stock performance. The new price target of $1.2 also suggests a potential decrease in the stock's value. This news is likely to have a negative impact on RAIN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100